Table 1.
Basic characteristics of the patient cohort
| Characteristics | Total=21 (%) |
|---|---|
| Age at diagnosis | |
| Median (range) | 45 (20-67) |
| Gender | |
| Female | 7 (33%) |
| Male | 14 (67%) |
| WHO Histology | |
| A | 5 (24%) |
| B1 | 3 (14%) |
| B2 | 4 (19%) |
| B3 | 3 (14%) |
| Thymic carcinoma | 6 (29%) |
| Masaoka_Stage | |
| I | 9 (43%) |
| IIA | 1 (5%) |
| IIB | 1 (5%) |
| III | 1 (5%) |
| IIIA | 5 (24%) |
| IVA | 2 (9%) |
| IVB | 2 (9%) |
| Smoking history | |
| Yes | 6 (29%) |
| No | 15 (71%) |
| AJCC_Stage | |
| I | 11 (52%) |
| II | 2 (10%) |
| IIIA | 4 (19%) |
| IVA | 4 (19%) |
| Adjuvant therapy after surgery | |
| YES | 12 (57%) |
| NO | 9 (43%) |
| Family History | |
| NO | 18 (85%) |
| Breast Cancer and Lung Cancer | 1 (5%) |
| ESCC and Thymomas | 1 (5%) |
| Liver Cancer | 1 (5%) |
| Complications | |
| MG | 5 (24%) |
| NO | 16 (76%) |
| Recurrence | |
| YES | 4 (19%) |
| NO | 16 (76%) |
| Unknown | 1 (5%) |
| Clinical Outcomes | |
| Alive | 18 (85%) |
| Death | 2 (10%) |
| Unknown | 1 (5%) |
| Metastatic Sites | |
| NO | 18 (85%) |
| Pleura and Lung | 1 (5%) |
| Lung | 1 (5%) |
| Liver | 1 (5%) |
Abbreviations: AJCC, American Joint Committee on Cancer; MG, myasthenia gravis.